Clinical trial · Observational
High-resolution Intra-operative PSMA PET-CT in Prostate Cancer
Perioperative Assessment of Intraoperative Margins and Lymph Node Invasion Using High-resolution 18F-PSMA-PET-CT in Prostate Cancer: a Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Single-center, diagnostic open-label prospective, pilot study in a total of 10 patients affected by Prostate cancer (PCa) with a risk of lymph node invasion (LNI) higher than 5% and candidates for a robot-assisted radical prostatectomy (RARP) with an extended pelvic lymph node dissection (ePLND) . The aim of the trial is to evaluate the feasibility and accuracy and clinical value of a novel high-resolution perioperative PET-CT-scan for intraoperative margin and lymph node invasion assessment, after 18F-PSMA injection, using histopathology as the gold standard.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AURA10® Specimen PET/CT imager | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To investigate the performance characteristics (sensitivity and specificity) of a novel high-resolution perioperative PET-CT-scan for intraoperative margins and lymph node invasion assessment after 18F-PSMA using histopathology as the gold standard
- timeFrame
- 1 YEAR
Secondary outcomes (1)
- measure
- Reporting positive lymph nodes detection rate at intraoperative imaging after 18-PSMA injection
- timeFrame
- 1 YEAR
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male patient, 18 years of age or older. 2. Patient is confirmed with high risk prostate cancer. 3. Patient is indicated to undergo radical prostatectomy and ePLND. 4. Patient is estimated compliant for study participation by the investigator. 5. Patient has freely given his/her informed consent to participate in this study. Exclusion Criteria: 1. Patient has general or local contra-indications for radical prostatectomy. 2. Patient has active viral or fungal infection. 3. Patient previously received radiotherapy of the prostate. 4. Patient participated in other clinical studies with radiation exposure of more than 1 mSv in the past year.
References
Publications (0)
Data not yet available